• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cellphire Therapeutics closes $15M Series A

April 5, 2021 By Sean Whooley

Cellphire TherapeuticsLong-term stabilization and platelet storage product developer Cellphire Therapeutics announced that it closed a $15 million Series A financing round.

Rockville, Md.-based Cellphire develops Thrombosomes and Cryopreserved Platelets (CPP) in bleeding patients. The former is a platelet-based, freeze-dried hemostatic agent, while CPP — frozen platelets — is being developed for the U.S. Army to fill a gap in military transfusion support, according to a news release.

CPP is complementary to the next-generation Thrombosomes product. Thrombosomes is touted as the only platelet-based, freeze-dried hemostatic agent in clinical trials, while Cellphire expects the product to potentially transform transfusion medicine with its shelf stability of three years.

Funds raised in the Series A round are earmarked for Cellphire to expand and accelerate the development of Thrombosomes while continuing R&D in targeted drug delivery, anti-thrombotic reversal and regenerative medicine.

Along with the news of the financing, Cellphire announced that Stephen H. Willard will step away from his role as CEO and his position on the board to allow for a new CEO to guide the company through its next phase. The board has identified the new CEO, the company said, while Rafael Jorda, will fill in as acting CEO until the new hire is brought on some time in the near future.

Jorda will also join the company’s board of directors along with two new additions, Thomas I.H. Dubin and Derek E. Woods. Dubin will serve as executive chairman.

Filed Under: Business/Financial News, Featured, Funding Roundup, Pharmaceuticals Tagged With: Cellphire Therapeutics

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS